Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.38 |
| ▸ | USP1 | O94782 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958714 | 0.89 | JAK2 (0.38) | JAK2ROCK2GSK3BMIFIRAK4 | |
| SCHEMBL19105581 | 0.81 | OPRM1 (0.41) | JAK2ROCK2GSK3BMIFIRAK4 | |
| SCHEMBL25825571 | 0.78 | EGLN2 (0.46) | EGLN1ACACB | |
| SCHEMBL24958753 | 0.74 | RAB9A (0.48) | MIF | |
| SCHEMBL12197739 | 0.73 | CHRNA7 (0.46) | CHRNA7 | |
| SCHEMBL24958718 | 0.73 | EGLN1 (0.35) | EGLN1ACACB | |
| SCHEMBL22862590 | 0.71 | MIF (0.57) | JAK2ROCK2GSK3BMIFUSP1 | |
| SCHEMBL22560233 | 0.71 | USP1 (0.40) | JAK2ROCK2GSK3BMIFUSP1 | |
| SCHEMBL20644392 | 0.69 | OGA (0.41) | EGLN1 | |
| SCHEMBL25045293 | 0.68 | MIF (0.56) | JAK2ROCK2GSK3BMIFCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | JAK2 1740/4885ROCK2 1674/4885GSK3B 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.